Stereotactic Radiosurgery Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Stereotactic Radiosurgery Market Trends and Insights

Rising Burden of Brain Metastases and Functional Neurological Disorders

The stereotactic radiosurgery market is benefiting from a broader patient pool than incidence counts alone suggest, because longer survival in breast, lung, and melanoma care is creating more cases with isolated or limited central nervous system recurrence. Those patients often fit stereotactic treatment better than whole-brain radiation or open surgery, which supports repeat procedure demand over time. This means the stereotactic radiosurgery market is seeing volume growth that is not fully visible through hardware installation counts alone. The neurological side of demand also widened when Elekta received U.S. FDA 510(k) clearance in July 2025 for refractory, drug-resistant mesial temporal lobe epilepsy in adults, which added a durable non-oncology use case to the installed base.^{[1]Elekta, “Elekta Receives U.S. FDA 510(k) Clearance for its Gamma Knife Radiosurgery System to Treat Patients with Refractory, Drug-Resistant Mesial Temporal Lobe Epilepsy,” Elekta Investor Press Release, elekta.com} That clearance matters because it opens a patient population that had been more dependent on invasive resection. It also gives the stereotactic radiosurgery market a recurring demand layer that is less exposed to oncology treatment cycles.

Shift Toward Non-Invasive, Outpatient Neuro-Oncology Care

The stereotactic radiosurgery market is moving toward same-day outpatient treatment as mask-based and frameless approaches replace older invasive workflows in many intracranial cases. This shift helps providers reduce admission burden while preserving local control, which makes radiosurgery easier to position against surgery in selected patients. The stereotactic radiosurgery market is also supported by new installations that make outpatient delivery more practical. Health Sciences Center Winnipeg deployed Elekta Esprit in January 2026 with integrated CT imaging, which removed the same-day MRI requirement and enabled fractionated treatment for larger tumors that had been harder to manage in a single session.^{[2]Health Sciences Centre Foundation, “New Gamma Knife for Minimally Invasive Brain Surgery Unveiled at Health Sciences Centre,” HSC Foundation Press Release, hscfoundation.mb.ca} Accuray widened access in Austria in May 2025 through the country’s first CyberKnife facility, and it also supported first patient treatments in Melbourne in October 2025 through its work with Icon Group, which signaled a broader East Coast expansion path in Australia.^{[3]Accuray Incorporated, “Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife System,” Accuray Press Release, prnewswire.com} These changes help the stereotactic radiosurgery market fit ambulatory care models that value short sessions, predictable throughput, and lower dependence on inpatient infrastructure.

AI-Enabled Treatment Planning and Workflow Automation

The stereotactic radiosurgery market is increasingly shaped by software because staffing limits at many centers now weigh more heavily than machine capacity. AI planning tools are addressing that bottleneck by reducing contouring effort, shortening planning time, and improving consistency across complex cases. At the AAPM 2026 Annual Meeting, the reasoning-based SAGE planning agent generated single-fraction SRS plans that were clinically indistinguishable from physician-approved human expert plans, and it showed statistically superior cochlear sparing in one cohort, which is relevant in lesions near the posterior fossa. These steps show that the stereotactic radiosurgery market is monetizing more of the planning layer instead of relying only on capital equipment cycles. They also support subscription and service revenue models that can expand even when new machine placements slow.

Reimbursement Support for High-Precision Radiation in Mature Markets

The stereotactic radiosurgery market remains stronger in mature healthcare systems because payment policy has moved closer to clinical practice across a defined set of indications. In the United States, CMS updated 2025 hospital outpatient payment rates by 2.9% under the Hospital Outpatient Prospective Payment System final rule, which supported equipment planning at facilities with higher Medicare exposure. Commercial payers often follow Medicare coverage patterns with a lag, so policy moves in the United States can influence the broader stereotactic radiosurgery market beyond public reimbursement alone. In Europe, national cancer plans and structural funding are widening access outside top academic hospitals, which expands the institutional buyer base. This support gives the stereotactic radiosurgery market a more stable path for replacement demand and selected new installations in mature regions.

High Capital Cost of Vaults, Shielding, and Platform Installation

The stereotactic radiosurgery market still faces a structural access problem because total project cost extends well beyond the headline price of the treatment platform. Shielded bunker construction can add USD 1 million to USD 3 million per installation, which is a major barrier for community oncology centers and stand-alone outpatient settings. This keeps much of the stereotactic radiosurgery market concentrated in better-funded institutions that can absorb both equipment and facility costs. Even so, the stereotactic radiosurgery market still runs on a global installed base where conventional infrastructure assumptions remain common. That means cost pressure continues to slow first-time adoption in lower-resource regions even as newer architectures gain visibility.

Cobalt-60 Supply Dependence for Gamma Knife Installations

The stereotactic radiosurgery market also faces a supply chain constraint that is specific to Gamma Knife installations. In November 2025, the Source Security Working Group warned the Office of the United States Trade Representative that proposed tariffs on Canadian-origin cobalt-60 would undermine U.S. healthcare capacity because domestic supply does not currently meet medical demand. Because cobalt-60 has a short half-life, inventory buffering is limited, and that makes concentration risk harder to manage. This issue is already influencing technology selection inside the stereotactic radiosurgery market, especially for first-generation installations where buyers are weighing supply resilience more directly. As a result, cobalt-free LINAC-based and robotic systems are receiving stronger consideration when procurement teams compare long-term operating risk.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Hardware Anchors Revenue, Software Lifts Recurring Monetization

Stereotactic radiosurgery systems held 51.24% of the stereotactic radiosurgery market share in 2025, which kept hardware at the center of revenue generation even as the business mix started to shift. The largest share still reflects the capital intensity of treatment platforms and the replacement cycle now underway at major academic centers. The stereotactic radiosurgery market is seeing this most clearly in Gamma Knife upgrades, where newer systems are replacing aging units rather than opening entirely new accounts. 

Treatment planning and simulation software is expected to be the fastest-growing product type at 6.36% CAGR through 2031, and that is changing how revenue is captured over the life of an installed system. Software is moving procurement toward subscriptions, upgrades, and service contracts that continue after the initial hardware sale. The stereotactic radiosurgery industry is therefore seeing value move into workflow intelligence, contouring, optimization, and treatment planning support rather than remaining concentrated in the machine alone. Services and supporting technologies still matter, but their role increasingly depends on the size and quality of the installed base that software is helping to monetize more effectively.

By Technology: Gamma Knife Leads Installed Depth, Robotic Systems Expand the Addressable Base

Gamma knife technology accounted for 41.27% of technology-segment revenue in 2025, which shows how strongly long clinical use, intracranial specialization, and installed-base depth still shape buying patterns. That leadership remains tied to academic center demand and to recurring replacement and source-related needs in mature markets. The stereotactic radiosurgery market still treats Gamma Knife as the benchmark for intracranial precision in many hospital settings. At the same time, the stereotactic radiosurgery market is giving more weight to technologies that ease infrastructure demands and widen placement opportunities beyond large referral centers. 

Robotic radiosurgery technology is projected to grow at 6.64% CAGR through 2031, which makes it the fastest-advancing technology segment in the stereotactic radiosurgery market. Growth is tied to cobalt-free and in some cases vault-light or vault-free positioning, which lowers the barrier for outpatient centers and specialty clinics. LINAC-based SRS remains the second-largest technology category because large radiation oncology departments can use shared infrastructure across conventional radiotherapy and radiosurgery. The stereotactic radiosurgery industry is therefore moving toward a technology comparison that weighs workflow, infrastructure, and resilience just as heavily as dose delivery performance.

By Application: Intracranial Demand Holds the Base, Spine and Functional Care Add the Growth Edge

Brain tumors accounted for 41.16% of the stereotactic radiosurgery market size in 2025, which kept intracranial oncology at the center of procedure demand. That leadership reflects the high volume of gliomas, meningiomas, acoustic neuromas, and especially brain metastases that remain well aligned with focused radiosurgical treatment. The stereotactic radiosurgery market still draws much of its core revenue from these established intracranial indications. The installed base, physician familiarity, and evidence history all reinforce that position across major hospital programs. 

Spinal tumors and lesions are forecasted to grow at 7.46% CAGR through 2031, which reflects broader use of stereotactic body radiation therapy for oligometastatic spine disease in patients less suited to open surgery. Arteriovenous malformations continue to provide a durable non-oncologic volume stream because treatment effect unfolds over time and follow-up imaging remains predictable. Trigeminal neuralgia is also gaining attention as patient preference increasingly favors non-invasive treatment over surgery in older or higher-risk populations. The stereotactic radiosurgery market is therefore broadening application demand without losing the intracranial case mix that built the category in the first place.

By End-User: Hospitals Retain the Base, Specialty Clinics Build Faster Momentum

Hospitals retained 40.53% of end-user revenue in 2025, which reflects their continued control over the largest treatment platforms, multidisciplinary referral pathways, and specialist staffing. That share also reflects the concentration of gamma knife and proton systems inside academic and large community medical centers. The stereotactic radiosurgery market still depends on hospitals for a large part of capital procurement and complex case handling. Hospitals also remain the main setting where payer policy, tumor board coordination, and replacement budgets come together in a single site of care. 

Specialty clinics and centers are projected to grow at 7.17% CAGR through 2031, which makes them the fastest-moving end-user group in the stereotactic radiosurgery market. Their rise is tied to compact robotic and advanced LINAC-based systems that fit stand-alone oncology settings more easily than traditional bunker-heavy models. Research and academic institutes remain the smallest end-user segment by revenue, yet they still shape clinical evidence, payer policy, and product design in ways that influence the entire stereotactic radiosurgery market.

Geography Analysis

North America held 44.27% of the stereotactic radiosurgery market share in 2025, which kept it as the largest regional contributor to current revenue. The United States supports that position through a dense concentration of academic cancer centers, ongoing replacement demand, and a CMS reimbursement structure that explicitly covers gamma knife, LINAC-based, and robotic stereotactic radiation therapy across defined intracranial indications. Payment clarity matters because it reduces hesitation around both utilization and capital planning in established programs. The stereotactic radiosurgery market in Canada also remains active, and Health Sciences Centre Winnipeg unveiled a USD 3.2 million Elekta Esprit system in January 2026 with integrated CT imaging and fractionation support for larger tumors. Mexico remains a smaller but advancing part of the regional stereotactic radiosurgery market, supported by private hospital expansion and medical tourism demand for advanced oncology procedures.

Europe ranks second in the stereotactic radiosurgery market, with Germany, the United Kingdom, France, Italy, and Spain accounting for the largest regional demand base. National cancer strategies and public funding support are widening access beyond top referral hospitals, which is helping secondary centers participate in precision radiotherapy adoption. France also strengthened its position as an early adopter with the late 2025 installation of the Varian Halcyon 5.0 platform with integrated real-time motion management at Institut du Cancer Avignon-Provence, while Italy continued its Esprit replacement cycle through active Gamma Knife upgrades.

Asia-Pacific is projected to post the fastest 8.33% CAGR in the stereotactic radiosurgery market size through 2031, which reflects a wider installation runway and rising investment in high-precision oncology infrastructure. China is a major part of that story after Accuray received dual NMPA approvals in January 2025, and the company stated that China may need around 2,000 radiation therapy systems over the next 5 years. India is also expanding its advanced treatment base, with IBA’s 2025 agreements with AIG Hospitals and Apollo Hospitals expected to add compact proton capacity and lift the country’s proton center count over time. Australia showed momentum in outpatient radiosurgery when Accuray and Icon Group supported first patient treatments in Melbourne in October 2025, while the Middle East, Africa, and South America remain smaller but active investment regions led by public-private oncology capacity additions.